CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

NCT03425279 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

245

Enrollment

INDUSTRY

Sponsor class

Conditions

Undifferentiated Pleomorphic Sarcoma
Myxofibrosarcoma

Interventions

BIOLOGICAL: CAB-AXL-ADC
BIOLOGICAL: PD-1 inhibitor

Sponsor

BioAtla, Inc.